Control of chronic neuropathic pain and allodynia
In one embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia by administering a therapeutically-effective amount of at least one LFA1 antagonist to the subject. In a preferred embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia, the method comprising administering intrathecally to the subject a therapeutically-effective amount of microparticles comprising PLGA-encapsulated pDNA-IL-10, optionally in combination with a therapeutically-effective amount of intrathecally-administered CpG oligodeoxynucleotide (CpG ODN) and/or at least one LFA1 antagonist.
1. A method of treating chronic neuropathic pain or chronic neuropathic pain in combination with allodynia in a subject in need comprising administering to said subject a therapeutically-effective amount of a composition comprising a LFA1 antagonist wherein said LFA1 antagonist is a compound according to the chemical structure:
a mixture thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, and wherein said LFA1 antagonist(s) is the only therapeutic agent useful for treating chronic neuropathic pain in said composition.
2. The method according to claim 1 which treats chronic neuropathic pain.
3. The method according to claim 2 wherein said neuropathic pain is peripheral neuropathic pain.
4. The method according to claim 1 wherein said LFA1 antagonist is BIRT-377 or a mixture of BIRT-377 and NorBIRT.
5. The method according to claim 1 wherein said LFA1 antagonist is BIRT-377.
6. The method according to claim 2 wherein said LFA1 antagonist is BIRT-377.
7. The method according to claim 3 wherein said LFA1 antagonist is BIRT-377.
8. The method according to claim 1 wherein said LFA1 antagonist is administered to said subject orally.
9. The method according to claim 1 wherein said LFA1 antagonist is administered to said subject parenterally.
10. The method according to claim 1 wherein said LFA1 antagonist is administered to said subject intrathecally.
11. The method according to claim 4 wherein said LFA1 antagonist is administered to said subject orally.
12. The method according to claim 4 wherein said LFA1 antagonist is administered to said subject parenterally.
13. The method according to claim 4 wherein said LFA1 antagonist is administered to said subject intrathecally.
14. The method according to claim 5 wherein said LFA1 antagonist is administered to said subject orally.
15. The method according to claim 5 wherein said LFA1 antagonist is administered to said subject parenterally.
16. The method according to claim 5 wherein said LFA1 antagonist is administered to said subject intrathecally.
17. The method according to claim 6 wherein said LFA1 antagonist is administered to said subject orally.
18. The method according to claim 6 wherein said LFA1 antagonist is administered to said subject parenterally.
19. The method according to claim 6 wherein said LFA1 antagonist is administered to said subject intrathecally.
20. The method according to claim 7 wherein said LFA1 antagonist is administered to said subject orally.
21. The method according to claim 7 wherein said LFA1 antagonist is administered to said subject parenterally.
22. The method according to claim 7 wherein said LFA1 antagonist is administered to said subject intrathecally.
23. A method of treating chronic neuropathic pain or chronic neuropathic pain in combination with allodynia in a subject in need comprising administering to said subject a therapeutically-effective amount of a composition comprising a LFA1 antagonist wherein said LFA1 antagonist is a compound according to the chemical structure:
or
a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, and wherein said LFA1 antagonist is the only therapeutic agent useful for treating chronic neuropathic pain in said composition.
24. The method according to claim 23 wherein said neuropathic pain is peripheral neuropathic pain and said composition is administered to said patient intravenously or intrathecally.
25. The method according to claim 23 wherein said LFA1 antagonist is BIRT-377 and said method treats chronic neuropathic pain.
26. The method according to claim 24 wherein said LFA1 antagonist is BIRT-377.